• " Deutsche Bank pharmaceuticals analyst Barbara Ryan says the impact of SEAS on Vytorin sales has been "negligible.

    FORBES: Magazine Article

  • "This was as good as it could get, " says Barbara Ryan at Deutsche Bank, noting that Pfizer won on both patents.

    FORBES: Magazine Article

  • "There was still supposed to be some inventory work-off in the first quarter, " says Barbara Ryan, an analyst at Deutsche Bank.

    FORBES: More Promises From Bristol-Myers

  • Prescriptions for the drugs are down more than 20%, according to a recent report by Deutsche Bank analyst Barbara Ryan, compared with late 2007.

    FORBES: Magazine Article

  • Barbara Ryan at Deutsche Bank also told investors that if a cheaper version of Plavix emerges, it means Lilly might have to charge less for prasugrel.

    FORBES: Plavix Pain

  • Barbara Ryan at Deutsche Bank wrote that the results were "as good as could be expected at this time, " and that shares will trade up for now.

    FORBES: Magazine Article

  • Barbara Ryan, the pharmaceuticals analyst at Deutsche Bank, wrote in a note to investors that she expects Pfizer to at least spin off the baby formula and o-t-c units.

    FORBES: Will Pfizer Break Up?

  • Barbara Ryan, an analyst at Deutsche Bank who attended the meeting, says she believed there would be a big study, like the one used to test Arcoxia's heart risk.

    FORBES: The Vioxx Safety Study Merck Didn't Do

  • Barbara Ryan, an analyst at Deutsche Bank (nyse: DB - news - people ), has written that in her opinion, the drug is no better than Actos.

    FORBES: Bristol, Merck Drug May Double Heart Risk

  • Both Deutsche Bank analyst Barbara Ryan and Kelly say it is worth betting on Pfizer Chief Executive JeffreyKindlerJeffrey Kindler's planned transformation, especially since Pfizer pays a healthy dividend that was hiked by 21% this year.

    FORBES: Magazine Article

  • Barbara Ryan, an analyst at Deutsche Bank who rates Pfizer stock a "buy, " says she expects the stock to "trade like a treasury bond" until Pfizer takes a big strategic step, like a major acquisition.

    FORBES: Losing Lipitor

  • Even if these medicines get to market, it seems unlikely that they will replace the sales that Wyeth will lose as existing blockbusters face generic competition, according to Barbara Ryan, the pharmaceuticals analyst at Deutsche Bank.

    FORBES: Wyeth's Worries

  • Barbara Ryan of Deutsche Bank wrote in a note to investors this morning that Schering-Plough is "no longer a growth story, but a cost-cutting one" and that she doesn't see the company's shares being awarded a higher multiple.

    FORBES: Schering Glitters, But Is It Gold?

  • In a note to investors on Friday, Barbara Ryan at Deutsche Bank wrote that higher doses of Actos "are just as efficacious as Pargluva, in our view, " and that the data expected from ProACTIVE could make things difficult for the newer drug.

    FORBES: Diabetes Drug Cuts Heart Attacks

  • Both Deutsche Bank (nyse: DB - news - people ) analyst Barbara Ryan and Kelly say it is worth betting on Pfizer Chief Executive Jeffrey Kindler 's planned transformation, especially since Pfizer pays a healthy dividend that was hiked by 21% this year.

    FORBES: Pfizer Cuts 10,000 Jobs

  • That's what happened to a 7-year-old white Arabian named William, said Santa Barbara Harbor Patrol Officer Ryan Kelly.

    CNN: Horse rescued after swimming 2 miles into ocean

$firstVoiceSent
- 来自原声例句
小调查
请问您想要如何调整此模块?

感谢您的反馈,我们会尽快进行适当修改!
进来说说原因吧 确定
小调查
请问您想要如何调整此模块?

感谢您的反馈,我们会尽快进行适当修改!
进来说说原因吧 确定